Arrowhead Pharmaceuticals (ARWR) Stock Analysis & AI Equity Report

Biotechnology USD Explore free reports

Arrowhead Pharmaceuticals (ARWR) overview

Arrowhead Pharmaceuticals (ARWR) stock analysis and AI equity research. For financial year 2026, Valuatum's model shows revenue of USD 451m and operating profit of USD -707m; the year-end share price was 65.45 USD and market capitalisation was USD 9,247m. Arrowhead Pharmaceuticals is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get Arrowhead Pharmaceuticals's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.

Key metrics & valuation multiples

Book valueUSD 50.3mFY 2026
Share price65.45 USDFY 2026 year end
RevenueUSD 451mFY 2026
Operating profitUSD -707mFY 2026
Net earningsUSD -724mFY 2026
Market capitalisationUSD 9,247mFY 2026 year end

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that silence genes associated with disease using RNA interference and a portfolio of RNA chemistries and delivery methods. Its marketed product, REDEMPLO, is used with diet to reduce triglycerides in adults with familial chylomicronemia syndrome. The company also develops drug candidates at various clinical stages and licenses or collaborates on programs it does not plan to commercialize independently.

Generate the Arrowhead Pharmaceuticals report

Arrowhead Pharmaceuticals is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.

Generate fresh report — €50.00 Delivered by email, usually within an hour

Sources & methodology

Financial figures are sourced from Valuatum's financial model for Arrowhead Pharmaceuticals and represent financial year 2026. See the methodology for the full Valuatum AI equity research framework.

Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.

Analyst reports on Arrowhead Pharmaceuticals

Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.